



Scottish Clinical Imaging network

# Scottish Clinical Imaging Network (SCIN)

INDICATIONS FOR USE OF  $^{18}\text{F}$ -FDG PET/CT IN  
THE MANAGEMENT OF PATIENTS WITH  
COLORECTAL CANCER

## Background

<sup>18</sup>F-FDG PET/CT has been shown in many studies to be more accurate than standard staging investigations using CT scanning for the detection of occult metastatic disease with previous guidance produced 2008 (revised 2020). This review is part of a planned revision of PET CT guidelines and takes into account latest evidence, clinical guidelines and expert opinion. There have been no significant alterations to the routine indications in the previous version of this document.

There is insufficient evidence to support PET/CT in the routine staging of all newly diagnosed colorectal tumours. All patients with metastatic colorectal cancer (mCRC) being considered for treatments with surgery or non-surgical therapy (chemotherapy and/or radiotherapy) are discussed and imaging reviewed at a colorectal cancer multidisciplinary team (MDT) meeting. Despite increasing interest in the use of PET CT to assess disease response to treatment there remains insufficient evidence to justify its routine use at this present time.

As with all cases, PET referrals should only be considered where the outcome of the investigation will directly influence individual patient management and treatment.

## Routine Indications

- Patients with apparently organ-restricted liver or lung metastases (either at primary presentation or during follow-up) who are being considered for resection. A PET/CT scan should be considered prior to the administration of cytoreductive chemotherapy.
- In selected patients with other sites of oligometastatic disease (e.g. peritoneal, adrenal) where treatment with curative intent is being considered following appropriate conventional imaging and MDT discussion.
- In patients with either rising CEA levels or clinically suspected local/presacral relapse where conventional imaging is negative/inconclusive
- In the staging of anal cancer with equivocal findings on conventional staging with CT/MRI and where PET CT would directly influence the patient's management

## Future Considerations

These guidelines will be reviewed on an ongoing basis to incorporate any change in existing evidence base, particularly with regards to disease response assessment.

## Scottish Clinical Imaging Network (SCIN)

Indications for the use of  $^{18}\text{F}$ -FDG PET/CT in the Management of Patients with Colorectal cancer

## References

ACCP (2007) Diagnosis and management of Lung Cancer Executive Summary: ACCP Evidence Based Clinical Practice Guidelines (2<sup>nd</sup> Ed) Chest 132 pp. 1-19.

Facey, K., Bradbury, I., Laking, G. and Payne, E. (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technology Assessment. 11 (44)

Fletcher, J.W et al (2008) Recommendations on the use of  $^{18}\text{F}$ -FDG PET in Oncology. The Journal of Nuclear Medicine 49 (3) pp. 480-491

Scottish Intercollegiate Guidelines Network (SIGN) (2011, updated 2016) Guideline 126. Diagnosis and Management of Colorectal Cancer: A National Clinical Guideline

Evidence-based indications for the use of PET-CT in the United Kingdom 2016. (RCR, RCPL, RCPSG, RCPE, BNMS, ARSAC) Published: May 2016

Colorectal cancer

NICE guideline. [NG151] Published: 29 January 2020

[www.nice.org.uk/guidance/ng151](http://www.nice.org.uk/guidance/ng151)